AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Scope & Guideline

Navigating the Landscape of Cancer Trials

Introduction

Explore the comprehensive scope of AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0277-3732
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1982 to 2024
AbbreviationAM J CLIN ONCOL-CANC / Am. J. Clin. Oncol.-Cancer Clin. Trials
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The American Journal of Clinical Oncology - Cancer Clinical Trials focuses on advancing the field of oncology through the dissemination of research related to clinical trials, treatment methodologies, and patient outcomes. The journal emphasizes rigorous clinical research, innovative therapeutic strategies, and the evaluation of treatment efficacy and safety.
  1. Clinical Trials in Oncology:
    The journal publishes original research related to clinical trials, focusing on the design, methodology, and outcomes of trials for various cancer treatments.
  2. Innovative Treatment Modalities:
    Research on novel therapeutic approaches, including immunotherapy, targeted therapy, and radiotherapy, aimed at improving patient outcomes.
  3. Patient Outcomes and Quality of Life:
    Emphasis on studies that assess the impact of cancer treatments on patient quality of life, survivorship, and long-term health effects.
  4. Epidemiology and Disparities in Cancer Care:
    Research addressing disparities in cancer treatment access, patient demographics, and outcomes across different populations.
  5. Translational Research:
    Studies that bridge laboratory findings with clinical applications, focusing on the translation of preclinical results into effective cancer therapies.
The journal has identified several trending and emerging themes that highlight the evolving landscape of cancer research and treatment. These areas reflect current challenges and innovations in oncology.
  1. Immunotherapy and Combination Therapies:
    An increasing number of studies are focusing on immunotherapy and its combination with other treatment modalities, reflecting a growing interest in harnessing the immune system to combat cancer.
  2. Real-World Evidence and Outcomes:
    Research utilizing real-world data to assess treatment effectiveness and patient outcomes is gaining traction, providing insights into the practical application of clinical trial results.
  3. Health Disparities and Access to Care:
    There is a heightened focus on understanding and addressing disparities in cancer treatment access and outcomes across different demographics and geographic regions.
  4. Personalized Medicine and Biomarkers:
    Emerging research is increasingly centered on the identification of biomarkers that can guide personalized treatment strategies, enhancing the effectiveness of therapies.
  5. Palliative Care and Quality of Life:
    A growing emphasis on studies that explore palliative care approaches and their impact on quality of life for cancer patients, particularly in advanced stages of the disease.

Declining or Waning

While the American Journal of Clinical Oncology - Cancer Clinical Trials has maintained a strong focus on various aspects of oncology, certain themes have seen a decline in prominence over recent years, possibly due to shifts in research priorities or advancements in technology.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decline in studies focusing solely on traditional chemotherapy regimens, as newer treatment modalities such as immunotherapy and targeted therapies gain more attention.
  2. Single-Agent Therapy Comparisons:
    Research comparing single-agent therapies has decreased, reflecting a trend towards combination therapies and multimodal approaches in cancer treatment.
  3. Basic Science Research:
    The journal has shifted its emphasis away from basic science studies that do not directly translate to clinical applications, focusing more on clinical trial outcomes and patient-related research.
  4. General Cancer Awareness Studies:
    Studies that broadly address cancer awareness without a specific clinical trial component are less frequently published, indicating a preference for research with direct clinical implications.

Similar Journals

CANCER TREATMENT REVIEWS

Empowering clinicians with vital therapeutic strategies.
Publisher: ELSEVIER SCI LTDISSN: 0305-7372Frequency: 10 issues/year

Cancer Treatment Reviews, published by Elsevier Science Ltd, is a leading international journal dedicated to the exploration and advancement of therapeutic strategies in oncology. With an impressive impact factor that reflects its status in the field, this journal is classified within Q1 quartile rankings in Medicine (Miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging, as of 2023. The journal has a rich lineage, having been established in 1974 and consistently evolving to encompass the latest breakthroughs and methodologies in cancer treatment. A vital resource for researchers, clinicians, and students alike, it aims to promote understanding and application of effective interventions, thereby contributing to improvements in patient outcomes. By prioritizing high-quality reviews, Cancer Treatment Reviews plays an essential role in bridging the gap between current research and clinical practice, making it an indispensable asset in the continuous fight against cancer.

Revista Colombiana de Cancerologia

Advancing Oncology Knowledge for a Healthier Tomorrow
Publisher: INST NACIONAL CANCEROLOGIAISSN: 0123-9015Frequency: 4 issues/year

Revista Colombiana de Cancerologia is a premier journal dedicated to advancing the field of oncology in Colombia and beyond. Published by the Instituto Nacional de Cancerología, this journal serves as a vital platform for the dissemination of high-quality research, comprehensive reviews, and innovative methodologies pertinent to cancer research and treatment. With an ISSN of 0123-9015 and E-ISSN 2346-0199, it aims to engage a diverse audience, including researchers, healthcare professionals, and students, fostering collaboration and knowledge sharing within the oncology community. Although specific metrics such as impact factors and H-index are currently unavailable, the journal is committed to maintaining high academic standards and encouraging open access to vital oncological insights. The Revista Colombiana de Cancerologia is positioned as an essential resource for those interested in the latest advancements in cancer care, prevention, and research methodologies, making significant contributions to the understanding and management of cancer.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Connecting Research and Practice in the Fight Against Cancer.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Therapeutic Advances in Medical Oncology

Pioneering open access to vital oncology research.
Publisher: SAGE PUBLICATIONS LTDISSN: 1758-8340Frequency: 1 issue/year

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

Cancer Research and Treatment

Empowering discoveries, enhancing treatments.
Publisher: KOREAN CANCER ASSOCIATIONISSN: 1598-2998Frequency: 4 issues/year

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

JNCI-Journal of the National Cancer Institute

Driving excellence in cancer research since 1940.
Publisher: OXFORD UNIV PRESS INCISSN: 0027-8874Frequency: 12 issues/year

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

Tumori Journal

Pioneering Discoveries for a Cancer-Free Future.
Publisher: SAGE PUBLICATIONS LTDISSN: 0300-8916Frequency: 6 issues/year

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

Clinical Genitourinary Cancer

Exploring breakthroughs in cancer treatment and management.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Journal of Thoracic Oncology

Pioneering Research for a Healthier Tomorrow
Publisher: ELSEVIER SCIENCE INCISSN: 1556-0864Frequency: 12 issues/year

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Oncology Letters

Elevating Oncology Discourse for Better Patient Outcomes
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.